Date published: 2026-1-11

1-800-457-3801

SCBT Portrait Logo
Seach Input

POLA2 Inhibitors

POLA2 inhibitors represent a class of chemical compounds that specifically target and inhibit the function of the POLA2 protein. POLA2, short for DNA polymerase alpha subunit B, plays a pivotal role in DNA replication, a fundamental process crucial for the maintenance of genomic integrity and the propagation of genetic information during cell division. Within the cellular DNA replication machinery, POLA2 forms a heterotetrameric complex with POLA1 (DNA polymerase alpha catalytic subunit) and the primase, PRIM1. This complex functions as the DNA polymerase alpha-primase complex and is responsible for initiating the synthesis of DNA strands during replication. In this context, POLA2 serves as a critical cofactor that interacts with POLA1, facilitating the efficient synthesis of short RNA-DNA primers required to initiate DNA replication. POLA2 inhibitors are designed to disrupt this essential interaction and, by extension, impair the normal progression of DNA replication.

The mechanism of action of POLA2 inhibitors typically involves the binding of these compounds to specific regions of POLA2 or its associated proteins, thereby inhibiting the formation of the functional POLA1-POLA2-PRIM1 complex. By doing so, these inhibitors hinder the initiation of DNA synthesis, leading to the accumulation of single-stranded DNA breaks, replication stress, and for genomic instability. Additionally, interference with POLA2's role in DNA replication may also have downstream effects on cell cycle progression and DNA repair mechanisms. As such, POLA2 inhibitors are valuable tools for studying the intricacies of DNA replication and its regulation in cellular contexts, shedding light on the fundamental processes underlying genome maintenance. Researchers utilize these inhibitors in laboratory settings to elucidate the molecular details of DNA replication and explore vulnerabilities that could be exploited for various scientific investigations beyond their applications.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Tamoxifen

10540-29-1sc-208414
2.5 g
$272.00
18
(2)

Selective estrogen receptor modulator (SERM) inhibiting estrogen binding to its receptor, preventing gene transcription.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Tyrosine kinase inhibitor targeting BCR-ABL fusion protein and c-Kit, inhibiting downstream signaling.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Epidermal growth factor receptor (EGFR) inhibitor blocking the EGFR kinase domain.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Multikinase inhibitor targeting RAF kinase and VEGFR, inhibiting tumor cell proliferation and angiogenesis.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1/JAK2 inhibitor blocking signaling pathways involved in cytokine-mediated inflammation.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

EGFR tyrosine kinase inhibitor inhibitng autophosphorylation and downstream signaling.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR/HER2 inhibitor, blocking phosphorylation of both receptors.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, inhibitng cell cycle progression in cancer cells.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor disrupting protein degradation and inducing apoptosis in cancer cells.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor disrupting anti-apoptotic signaling in leukemia cells.